

Medical step therapy updates

Effective March 1, 2022, FDA-approved biosimilar agents to Avastin, Mvasi, and Zirabev will not be included in the preferred product step.

Step therapy review will apply upon precertification initiation, in addition to the current medical necessity review, as is current procedure. Step therapy will not apply for members who are actively receiving the nonpreferred medications listed below.

Clinical Criteria are publicly available on the provider website. Visit the [Clinical Criteria](#) page to search for specific criteria.

Clinical Criteria	Preferred drug(s)	Nonpreferred drug(s)
INC-CC-0072	Avastin Eylea	Lucentis Macugen Beovu

<https://providers.anthem.com/ca>